CN113667608B - 一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用 - Google Patents
一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用 Download PDFInfo
- Publication number
- CN113667608B CN113667608B CN202110330475.7A CN202110330475A CN113667608B CN 113667608 B CN113667608 B CN 113667608B CN 202110330475 A CN202110330475 A CN 202110330475A CN 113667608 B CN113667608 B CN 113667608B
- Authority
- CN
- China
- Prior art keywords
- ttys
- microorganisms
- china
- culture collection
- ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000025865 Ulcer Diseases 0.000 title abstract description 24
- 231100000397 ulcer Toxicity 0.000 title abstract description 24
- 238000011282 treatment Methods 0.000 title abstract description 12
- 241000605118 Thiobacillus Species 0.000 title abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract description 7
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 240000005995 Laetiporus sulphureus Species 0.000 claims abstract description 18
- 235000007714 Laetiporus sulphureus Nutrition 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 241000722824 Ardisia crenata Species 0.000 claims abstract description 13
- 244000005700 microbiome Species 0.000 claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims abstract description 12
- 230000004151 fermentation Effects 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 10
- 238000009629 microbiological culture Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000000813 microbial effect Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 8
- 241000993291 Armillariella Species 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000009630 liquid culture Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 241000216674 Armillaria tabescens Species 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 20
- 239000011593 sulfur Substances 0.000 abstract description 17
- 229910052717 sulfur Inorganic materials 0.000 abstract description 17
- 229910052956 cinnabar Inorganic materials 0.000 abstract description 13
- 241000233866 Fungi Species 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000009977 dual effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000007107 Stomach Ulcer Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 7
- 201000005917 gastric ulcer Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 208000004232 Enteritis Diseases 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000222689 Laetiporus Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- ILRLTAZWFOQHRT-UHFFFAOYSA-N potassium;sulfuric acid Chemical compound [K].OS(O)(=O)=O ILRLTAZWFOQHRT-UHFFFAOYSA-N 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 241000009794 Agaricomycetes Species 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000605272 Acidithiobacillus thiooxidans Species 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 241000722826 Ardisia Species 0.000 description 1
- 241000726094 Aristolochia Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000758536 Dikarya Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及微生物技术领域,尤其涉及一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用。本发明的朱红硫磺菌(Laetiporus sulphureus)ttys‑997已于2020年12月3日保藏于中国微生物菌种保藏管理委员会普通微生物中心,分类学命名为朱红硫磺菌(Laetiporus sulphureus),保藏编号为:CGMCCNo.21084,保藏地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所。本发明的朱红硫磺菌ttys‑997,属于纯天然绿色食用菌,是一种营养丰富、食药兼用的珍贵大型真菌。利用该菌发酵制备得到的液体制剂,对消化道溃疡和结肠炎治疗效果显著。
Description
技术领域
本发明涉及微生物技术领域,尤其涉及一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用。
背景技术
朱红硫磺菌,中文别名硫色多孔菌朱红色变种、红色硫黄菌、鸡冠菌等,属担子菌门(Basidiomycota),伞菌亚纲(Agaricomycetes),非褶菌目(Polyporales),硫磺菌属(Laetiporus),广泛分布于我国黑龙江、河北、四川、西藏、新疆、台湾等地区,是大型珍稀食药兼用真菌。子实体幼嫩至成熟时可食用,味道鲜美,营养丰富,老后呈干酪状,不宜食用,但可入药,性温,味甘,具有提高人体免疫力等多种功效。目前朱红硫磺菌的生产主要以菌包栽培为主,受产地环境条件影响较大,且受季节限制,产量全年分布不均,加上朱红硫磺菌自身生态的特殊性和复杂性,以及外部条件制约,资源匮乏,使人们难以大量获得这一珍贵的资源。采用液体深层发酵获得真菌菌丝体及液体制剂的方式是近年发展起来的人工获取珍稀真菌的新方法,不受季节限制,易于人工控制,生产周期短,生产速度高,有效成分含量高,成本低和具有实现规模化和集约化的优势,更具发展前景。然而,目前还没有适用于朱红硫磺菌的液体深层发酵技术,更不能大规模生产,本领域需要建立一种高效、快速的培养方式。
消化道溃疡和结肠炎是全球常见病,可发生于食管、胃、十二指肠、结肠等部位,可发于任何年龄段,主要病因是幽门螺杆菌感染、长期服用糖皮质激素、化疗药物以及应激反应、吸烟、饮酒、长期精神紧张及不规律饮食习惯等。腹痛、腹泻、便血或者不适的感觉是该病的主要症状。这是一类具有反复发作倾向的慢性病,病程长者可达一、二十年,高龄患者一旦并发大量出血、穿孔或幽门梗阻,病情较凶险,少数患者可发生癌变,则预后较差。目前治疗困难,且容易复发。本领域需要新的治疗方法。
发明内容
本发明的目的在于克服现有技术的不足,提供一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用,利用该菌发酵制备得到的液体制剂,对消化道溃疡和结肠炎治疗效果显著。
为实现上述目的,本发明采取的技术方案为:提供一株朱红硫磺菌(Laetiporussulphureus)ttys-997,所述朱红硫磺菌(Laetiporus sulphureus)ttys-997已于2020年12月3日保藏于中国微生物菌种保藏管理委员会普通微生物中心,分类学命名为朱红硫磺菌(Laetiporus sulphureus),保藏编号为:CGMCC No.21084,保藏地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所。
本发明还提供所述朱红硫磺菌ttys-997在制备治疗消化性溃疡的药物或食品中的应用。
本发明还提供所述朱红硫磺菌ttys-997在制备治疗结肠炎的药物或食品中的应用。
本发明还提供一种包含所述朱红硫磺菌ttys-997的微生物菌剂。
作为本发明所述微生物菌剂的优选实施方式,所述微生物菌剂为片剂、胶囊剂、口服液或冻干粉剂。
作为本发明所述微生物菌剂的优选实施方式,所述微生物菌剂为将所述的朱红硫磺菌ttys-997进行发酵得到。
作为本发明所述微生物菌剂的优选实施方式,所述微生物菌剂的制备方法具体包括以下步骤:
(1)按5-10%的比例向培养基中接种所述朱红硫磺菌ttys-997的种子液,20-32℃搅拌培养4-6天,使其菌体浓度达到30-40%,pH2-3,获得发酵液;
(2)将发酵液离心,得上清液,用纯净水与上清液混合至pH5~6,灭菌后即得微生物菌剂。
作为本发明所述微生物菌剂的优选实施方式,所述培养基包括以下组分:土豆水煮液15-30%,蛋白胨2-4%,葡萄糖10-25%,黄豆粉10-15%,牛肉膏1-3%,硫酸二氢钾0.1-0.3%,蒸馏水1L,pH自然。
作为本发明所述微生物菌剂的优选实施方式,所述朱红硫磺菌ttys-997的种子液为将所述朱红硫磺菌ttys-997接种在固体斜面培养基上,培养,得到菌种斜面培养物;将斜面培养物接到液体培养基中培养,得到种子液。
本发明的有益效果:
本发明的朱红硫磺菌(Laetiporus sulphureus)ttys-997,生长能力旺盛,采用现代化发酵罐生产技术,可明显缩短生长周期,降低生产成本,提高有效成分产量。利用该菌发酵制备得到的液体制剂,将该液体制剂喂饲醋酸湿敷法制备的慢性胃溃疡大鼠,可显著降低溃疡面积与溃疡体积,且呈剂量效应关系,对胃溃疡有明显治疗作用;将该液体制剂喂饲硫酸葡聚糖钠制备的慢性结肠炎大鼠,可明显降低粪便评分及肠炎评分,并可显著降低相关炎性因子,且呈剂量效应关系,对结肠炎有较好的治疗作用。
生物材料保藏
本发明的朱红硫磺菌(Laetiporus sulphureus)ttys-997,已于2020年12月3日保藏于中国微生物菌种保藏管理委员会普通微生物中心,分类学命名为朱红硫磺菌(Laetiporus sulphureus),保藏编号为:CGMCC No.21084,保藏地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所。
附图说明
图1:朱红硫磺菌(Laetiporus sulphureus)ttys-997扩增的18S rDNA-ITS序列基因比对结果图。
图2:朱红硫磺菌(Laetiporus sulphureus)ttys-997扩增的ITS序列结果。
具体实施方式
为更清楚地表述本发明的技术方案,下面结合具体实施例进一步说明,但不能用于限制本发明,此仅是本发明的部分实施例。
实施例1菌株的筛选与鉴定
朱红硫磺菌ttys-997的培养基:土豆水煮液15-30%,蛋白胨2-4%,葡萄糖10-25%,黄豆粉10-15%,牛肉膏1-3%,硫酸二氢钾0.1-0.3%,蒸馏水1L,pH自然。
朱红硫磺菌ttys-997的培养特征:朱红硫磺菌ttys-997在固体培养基上生长旺盛,菌丝浓密,25-28℃培养,菌落圆形,表面干燥,5d开始大量生成气生菌丝,并产生黄色色素。
提取菌株ttys-997的基因组DNA,以NS1、NS6、ITS1、ITS4-R为引物进行PCR(表1),扩增菌株的18S rDNA和ITS序列(序列如SEQ ID NO:1所示)。纯化后进行基因测序,并将所测序列与Genbank中的rDNA序列比较,该菌株被鉴定为Laetiporus(硫磺菌属),为Laetiporus sulphureus(朱红硫磺菌)。其分类单元为:Eukaryota;Fungi;Dikarya;Basidiomycota;Agaricomycotina;Agarico mycetes;Ployporales;Laetiporus.最终确定ttys-997为朱红硫磺菌。
表1引物序列
引物名称 | 引物序列 | 编号 |
NS1 | GTAGTCATATGCTTGTCTC | SEQ ID NO:2 |
NS6 | GCATCACAGACCTGTTATTGCCTC | SEQ ID NO:3 |
ITS1 | TCCGTAGGTGAACCTGCGG | SEQ ID NO:4 |
ITS4-R | TCCTCCGCTTATTGATATGC | SEQ ID NO:5 |
本发明的朱红硫磺菌(Laetiporus sulphureus)ttys-997,已于2020年12月3日保藏于中国普通微生物菌种保藏管理中心,分类学命名为朱红硫磺菌(Laetiporussulphureus),保藏编号为:CGMCC No.21084,保藏地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所。
实施例2朱红硫磺菌ttys-997液体制剂的制备
朱红硫磺菌ttys-997的培养基:土豆水煮液15-30%,蛋白胨2-4%,葡萄糖10-25%,黄豆粉10-15%,牛肉膏1-3%,硫酸二氢钾0.1-0.3%,蒸馏水1L,pH自然。
朱红硫磺菌ttys-997液体制剂的制备具体包括以下步骤:
(1)在上述斜面培养基上接菌,于25-28℃培养5-8d,得到斜面培养物;将新鲜斜面培养物接到上述液体培养基中,22-25℃培养4-5d,得到种子液;然后将种子液按照5-10%浓度接种到发酵罐中。
(2)在发酵罐子中放入纯净水,加入上述培养基成分,高温加热后维持100-120℃,保温20-30min,降温至室温,按5-10%接种,20-32℃搅拌培养4-6d,使其菌体浓度达到30-40%,pH 2-3,室温下放罐,获得发酵液。
(3)将发酵液置于离心机中3000-5000rpm,离心30min,得上清液。用纯净水与上清液混合稀释,至pH 5~6。置于灭菌锅中,高温加热后维持113-115℃,保温30min,灭菌后即得液体制剂。
实施例3朱红硫磺菌ttys-997对胃溃疡的治疗情况
以大鼠为模型动物,醋酸湿敷法构建胃溃疡动物模型,研究ttys-997液体制剂对胃溃疡的治疗情况。
1实验动物
SD大鼠,雄性180-220g。饲养环境:22±2℃,湿度为45~65%,12h昼夜交替;自由进食与饮水。
2实验方案
2.1造模
将大鼠适应性饲养7天后,将动物禁食不禁水24小时,乙醚麻醉后于剑突下切开腹腔,将胃轻拉出腹腔外,用直径5mm的圆滤纸片浸适量醋酸,在胃窦部浆膜层贴敷10s三次,缝合切口,术后单笼饲养3天。
2.2分组及给药
选取手术成功的大鼠60只,按照体重随机分为对照组、模型组、ttys-997低、中、高剂量组(2mL/100g,4mL/100g,8mL/100g)、兰索拉唑5mg/kg组,每组10只。各组按相应剂量灌胃给药,连续14天。
2.3取材
末次给药后禁食24小时,动物处死,取出整个胃浸泡于10%的甲醛内,浸泡20分钟后沿胃大弯剪开,洗净内容物,取腺胃区展开平铺于玻璃板上,用纸吸干溃疡内的水分,测量其面积和体积。
2.4检测指标
观察记录溃疡面积、体积。溃疡面积测量方法:于带标尺的解剖显微镜下计数溃疡所占的方格数,换算成面积。体积测量法:用微量注射器将有色墨水注入溃疡内,将溃疡填满与周边平齐,读取微量注射器上刻度即为溃疡的体积。
2.5统计学分析
数据采用SPSS 21.0分析软件进行分析,实验结果以平均值±标准差(mean±SD)表示。多组均数之间的比较采用单因素方差分析(One-Way ANOVA)评价整体方差差异,并用LSD进行多重比较。对于两组间比较,采用非配对t检验进行比较。定义P<0.05为显著性差异。
3实验结果
表2ttys-997对胃溃疡大鼠的溃疡发生率、溃疡面积及溃疡体积的治疗作用(mean±SD)
注:**P<0.01vs.Control group;#P<0.05,##P<0.01vs.Model group。
由表2可知,与对照组相比,模型组溃疡面积、溃疡体积均有显著性升高,说明胃溃疡模型制备成功;与模型组相比,兰索拉唑组、997中、高剂量组溃疡面积均显著下降,且呈剂量效应关系;与模型组相比,兰索拉唑组、997低、中、高剂量组溃疡体积均显著下降,且呈剂量效应关系;以上结果表明朱红硫磺菌菌液对醋酸湿敷法制备的胃溃疡模型具有治疗作用。
实施例4朱红硫磺菌ttys-997对肠炎的治疗作用
以大鼠为模型动物,灌胃给予5%硫酸葡聚糖钠构建结肠炎模型,研究ttys-997液体制剂对肠炎的治疗作用。
1实验动物
SD大鼠,雄性180-220g。饲养环境:22±2℃,湿度为45~65%,12h昼夜交替;自由进食与饮水。
2实验方案
2.1造模
单笼饲养,除空白组外,其余5组用5%硫酸葡聚糖钠(0.75g/kg)连续灌胃10天,每日1次,空白组给予等量生理盐水。
2.2分组及给药
大鼠按照体重随机分为空白组、模型组、ttys-997低、中、高剂量组、整肠生0.15g/kg,每组10只。从第1天灌胃硫酸葡聚糖钠开始,隔8小时后分别灌胃给药,共14天。
2.3取材
取材前一天,单笼饲养,观察粪便形态,用粪便潜血试剂盒测定并评分。大鼠最末次给药后禁食12小时,乙醚麻醉,下腔静脉取血,用于IL-6、TNF-α测定。解剖剪取结肠,剪开肠腔,生理盐水冲洗后用滤纸吸干,观察结肠情况并进行评分。
2.4检测指标
粪便评分,结肠评分,血清IL-6与TNF-α含量情况。
表3粪便评分标准
表4结肠评分标准
2.5统计学分析
数据采用SPSS 21.0分析软件进行分析,实验结果以平均值±标准差(mean±SD)表示。多组均数之间的比较采用单因素方差分析(One-Way ANOVA)评价整体方差差异,并用LSD进行多重比较。对于两组间比较,采用非配对t检验进行比较。定义P<0.05为显著性差异。
3实验结果
表5ttys-997对大鼠粪便评分与结肠评分的影响(mean±SD)
注:**P<0.01vs.Control group;#P<0.05,##P<0.01vs.Model group。
如表5所示,与对照组相比,模型组粪便评分与结肠评分均显著升高,说明肠炎模型制备成功;与模型组相比,整肠生0.15g/kg组粪便评分与结肠评分显著降低(P<0.01),997中剂量组、高剂量组粪便评分与结肠评分显著降低(P<0.05;P<0.01)且呈剂量效应关系。
表6朱红硫磺菌ttys-997对大鼠血清IL-6与TNF-α水平的影响(mean±SD)
注:**P<0.01vs.Control group;#P<0.05,##P<0.01vs.Model group。
如表6所示:与对照组相比,模型组IL-6与TNF-α均显著升高;与模型组相比,整肠生0.15g/kg组IL-6与TNF-α均显著降低(P<0.01),997中剂量组、高剂量组IL-6与TNF-α显著降低(P<0.05;P<0.01)且呈剂量效应关系。
本实施例的结果表明,朱红硫磺菌ttys-997对硫酸葡聚糖钠致大鼠结肠炎有较好的治疗作用。
以上各结果充分说明,本发明提供的朱红硫黄菌ttys-997及其制备的液体制剂对消化道溃疡、结肠炎有显著的治疗效果,起效快,绿色、安全、可靠,具有良好的经济效益和社会效益。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
SEQUENCE LISTING
<110> 孙长春
<120> 一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用
<130> 2021.3.22
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 578
<212> DNA
<213> 朱红硫磺菌(Laetiporus sulphureus)
<400> 1
tgcggaagga tcattaacga acaacggggt tcgccccttg tccacaaaca cacccccgtg 60
cacgttgaag gcccggctcg ttgagtgggt gggcgaccgc ccaggattcg tagcctcgct 120
ttcttacaca aacttcagaa tgtacatcag aatgtcttac gcgtgtaacg catcgtaata 180
taactttcag caacggatct cttggctctc gcatcgatga agaacgcagc gaaatgcgat 240
aagtaatgtg aattgcagaa ttcagtgaat cattgaatct ttgaacgcac cttgcgctcc 300
ttggcattcc gaggagcatg cctgtttgag tgtcatgaaa ctctcaaccc ctgccatctt 360
tgcggatgag cgtcggttgg attttggagg ttgccggact cgttcggctc ctcttgaaag 420
catagtaaag cttggacctg accgaccggg tggacgtgat agaaagtcac cgtcgaccga 480
agggtccgtc gctgaacggt tcaagctttg tttgtcgtct tcggacgaac atctctgacc 540
tctgacctca aatcaggtag gactacccgc tgaactta 578
<210> 2
<211> 19
<212> DNA
<213> 人工合成
<400> 2
gtagtcatat gcttgtctc 19
<210> 3
<211> 24
<212> DNA
<213> 人工合成
<400> 3
gcatcacaga cctgttattg cctc 24
<210> 4
<211> 19
<212> DNA
<213> 人工合成
<400> 4
tccgtaggtg aacctgcgg 19
<210> 5
<211> 20
<212> DNA
<213> 人工合成
<400> 5
tcctccgctt attgatatgc 20
Claims (3)
1.朱红硫磺菌ttys-997在制备治疗消化性溃疡的药物中的应用;
所述朱红硫磺菌(Laetiporus sulphureus)ttys-997已于2020年12月3日保藏于中国微生物菌种保藏管理委员会普通微生物中心,分类学命名为朱红硫磺菌(Laetiporussulphureus),保藏编号为:CGMCC No.21084,保藏地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所。
2.一种微生物菌剂的制备方法,其特征在于,所述微生物菌剂的制备方法具体包括以下步骤:
(1)按5-10%的比例向培养基中接种朱红硫磺菌ttys-997的种子液,20-32℃搅拌培养4-6天,使其菌体浓度达到30-40%,pH2-3,获得发酵液;
(2)将发酵液离心,得上清液,用纯净水与上清液混合至pH5~6,灭菌后即得微生物菌剂;
所述朱红硫磺菌(Laetiporus sulphureus)ttys-997已于2020年12月3日保藏于中国微生物菌种保藏管理委员会普通微生物中心,分类学命名为朱红硫磺菌(Laetiporussulphureus),保藏编号为:CGMCC No.21084,保藏地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所。
3.根据权利要求2所述微生物菌剂的制备方法,其特征在于,所述朱红硫磺菌ttys-997的种子液为将所述朱红硫磺菌ttys-997接种在固体斜面培养基上,培养,得到菌种斜面培养物;将斜面培养物接到液体培养基中培养,得到种子液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110330475.7A CN113667608B (zh) | 2021-03-24 | 2021-03-24 | 一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110330475.7A CN113667608B (zh) | 2021-03-24 | 2021-03-24 | 一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113667608A CN113667608A (zh) | 2021-11-19 |
CN113667608B true CN113667608B (zh) | 2023-08-22 |
Family
ID=78538057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110330475.7A Active CN113667608B (zh) | 2021-03-24 | 2021-03-24 | 一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113667608B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1281700A (zh) * | 1999-07-23 | 2001-01-31 | 李洋 | 一种调理胃肠功能的硫磺菌制剂及其生产方法 |
CN103961379A (zh) * | 2014-05-15 | 2014-08-06 | 神农架天润生物科技有限责任公司 | 一种硫磺菌提取物及用途 |
CN110179831A (zh) * | 2019-05-07 | 2019-08-30 | 三峡大学 | 硫磺菌提取物的制药用途 |
CN113717859A (zh) * | 2021-03-17 | 2021-11-30 | 孙长春 | 一种朱红硫磺菌及其应用 |
-
2021
- 2021-03-24 CN CN202110330475.7A patent/CN113667608B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1281700A (zh) * | 1999-07-23 | 2001-01-31 | 李洋 | 一种调理胃肠功能的硫磺菌制剂及其生产方法 |
CN103961379A (zh) * | 2014-05-15 | 2014-08-06 | 神农架天润生物科技有限责任公司 | 一种硫磺菌提取物及用途 |
CN110179831A (zh) * | 2019-05-07 | 2019-08-30 | 三峡大学 | 硫磺菌提取物的制药用途 |
CN113717859A (zh) * | 2021-03-17 | 2021-11-30 | 孙长春 | 一种朱红硫磺菌及其应用 |
Non-Patent Citations (1)
Title |
---|
齿孔酸对大鼠佐剂型关节炎的影响;汪鋆植等;《中药药理与临床》;20161231;第32卷(第2期);23-27 * |
Also Published As
Publication number | Publication date |
---|---|
CN113667608A (zh) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107488598B (zh) | 一种牛蒡基蛹虫草菌丝体及其制备方法 | |
WO2019080454A1 (zh) | 一株桦褐孔菌及其应用 | |
CN101829159A (zh) | 一种富硒猴头菌菇胶囊的制备方法 | |
CN115287240A (zh) | 一株具有高尿酸血症及痛风防治作用的植物乳杆菌及其应用 | |
CN114908020B (zh) | 一种抗幽门螺旋杆菌感染的植物乳杆菌及其在食用本草酵素产品中的应用 | |
TWI711458B (zh) | 植物發酵物及其製備方法與用於胃臟保健的用途 | |
CN114107134A (zh) | 一株侧孢短芽孢杆菌及其应用 | |
CN106038614B (zh) | 蛹虫草多糖食用菌酵素复方饮液及其制备方法 | |
KR101396842B1 (ko) | 오미자 발효물 및 이를 포함하는 항균 및 면역 증강 조성물 | |
CN113667608B (zh) | 一株朱红硫磺菌及其在治疗消化道溃疡和结肠炎中的应用 | |
CN107468835A (zh) | 微生物发酵蒲黄的组合物及其应用 | |
CN114525233B (zh) | 清酒乳杆菌和水苏糖组合物在制备便秘治疗药物中的应用 | |
CN109329612A (zh) | 一种复合饲料添加剂及其制备方法 | |
CN104498310A (zh) | 一种猴头菇醋制备方法 | |
CN114854604A (zh) | 一种肉灵芝、包含肉灵芝的高浓度口服液及其制备方法 | |
CN113355259A (zh) | 一株格氏乳杆菌及其在治疗消化性溃疡中的应用 | |
CN107349376B (zh) | 一种抗鸡球虫益生药物及其制备方法和应用 | |
CN115044498B (zh) | 一株适于发酵红枣饮料的植物乳杆菌株及其应用 | |
CN111019854B (zh) | 一种橘皮果渣发酵剂及含橘皮果渣的母猪发酵饲料 | |
CN116970501B (zh) | 一种三联菌固态发酵制剂及其制备方法和应用 | |
CN114591846B (zh) | 圣女果虫草复合体及其制备方法和应用 | |
CN115895941B (zh) | 一株鼠李糖乳杆菌及其应用 | |
CN115873743B (zh) | 一株高产尿囊素的发酵粘液乳杆菌及其应用 | |
CN117084324B (zh) | 居冰菌在大西洋鲑养殖中的应用 | |
CN112813002B (zh) | 一株耐热短乳杆菌及其后生素制剂的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |